The production of monosodium glutamate has grown from a by-product of the sugar beet industry to an important position in today’s food commodities. Monosodium glutamate is made from Steffan's waste, corn gluten, wheat gluten, and other similar proteinaceous materials. In trying to find moro and better uses for soybeans, it was discovered that soybean meal was an excellent raw material for making monosodium glutamate because of the high percentage of proteins in the meal . For years in the Far East, soybean meal has been utilized for the production of monosodium glutamate, but American industry had to be educated to make use of the potential of the soybean. For the various processes required for the isolation and purification of glutamic acid for the conversion into monosodium glutamate, the yields obtained have been low of the order of between 50 and 70 percent by weight of the total glutamic acid originally contained in the proteinaceous substances processed. The difficulty involved in the manufacture of monosodium glutamate is in getting the glutamic acid in a refined state. Other amino acids are obtained during the initial hydrolysis step, and they are difficult to remove to obtain the "edible" glutamic acid of commerce. The proposed production of monosodium glutamate from soybean meal is an answer to higher yields and less expensive equipment and reagents. In using the soybean meal, which is itself a highly valuable cattle food, the glutamic acid is taken out leaving valuable amino acids in the waste after the initial hydrolysis step. Therefore, this waste referred to as humin can be sold as a hydrolyzed cattle food. It was the purpose of this investigation to design a pilot plant for the production of monosodium glutamate. The problem involved the investigation of synthesis methods and conditions, cost analyses, and actual design of the pilot plant. / Master of Science

NMDA glutamate receptor is a ligand-gated ion channel that mediates a major component of excitatory neurotransmission in the central nervous system (CNS). NMDA receptors are activated by simultaneous binding of two different agonists, glutamate and glycine/ D-serine1. With aging, glutamate concentration gets altered, giving rise to glutamate toxicity that contributes to age-related pathologies like Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and dementia88,95. Some treatments for these conditions include NMDA receptor blockers like memantine130. However, when completely blocking the receptors, there is a restriction of the receptor's normal physiological function59. A different approach to regulate NMDAR receptors is thorough allosteric modulators that could allow cell type or circuit-specific modulation, due to widely distributed GluN2 expression, without global NMDAR overactivation59,65,122. In one study, we hypothesized that the compound CNS4 selectively modulates NMDA diheteromeric receptors (GluN2A, GluN2B, GuN2C, and GluN2C) based on (three) different glutamate concentrations. Electrophysiological recordings carried out on recombinant NMDA receptors expressed in xenopus oocytes revealed that 30μM and 100μM of CNS4 potentiated ionic currents for the GluN2C and GluN2D subunits with 0.3μM Glu/100μM Gly. However, when using 300μM Glu/100μM Gly, CNS4 inhibited the relative response in the GluN2D subunit and had no effect on the remaining subunits. CNS4 reduced the response to glutamate alone for GluN2A but increased it for GluN2B and did not appear to replace glutamate. Another set of electrophysiological recordings measuring current-voltage relationship was made in order to understand ion flow across the channel in the presence of CNS4. 100μM CNS4 numerically increased the ionic inward current through the channel pore with more positive membrane potential, reflected by a significant difference in reversal potential values, in the GluN2C and GluN2D subunits. CNS4 also exhibited a non-voltage dependent activity and it did not appear to compete with magnesium which naturally blocks the receptor. Finally, the effect of CNS4 on calcium uptake and cellular viability was study in neurons from primary rat brain culture. Cortial and striatal neurons were given excessive doses of synthetic agonist NMDA in order to hyperactivate native NMDAR. In the calcium assay, 100µM of CNS4 significantly increased calcium upatake when given with 300µM NMDA compared with NMDA alone in cortex and when given with 100µM and 300µM NMDA in striatum. In the MTS assay, CNS4 did not alter neuronal viability in either cortical or striatal neurons compared with NMDA alone. Also, when CNS4 was used in non treated neurons it did not alter neuronal viability. Findings from the primary brain culture let us conclude that CNS4 could facilitate calcium influx and possibly be non toxic for neurons. / Master of Science / NMDA ionotropic glutamate receptors are predominately expressed in the central nervous system (CNS). These receptors are activated by glutamate and glycine/ D-serine1. With aging, glutamate concentration in the synapse gets altered giving rise to toxic environments for neurons that can contribute to age-related pathologies like Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and dementia88,95. Some treatments of these conditions include the receptor blockers like memantine130. However, when completely blocking the receptors, there is a restriction of the receptor's normal physiological function59. A different approach to regulate NMDAR is through allosteric modulators that are compounds that modulate the receptor function without competing with endogenous agonists59,65,122. In this study, we hypothesized that the compound CNS4 selectively modulates NMDAR based on glutamate concentration. Electrophysiological recordings on stage four xenopus oocytes helped us to identify the dose-dependent activity of CNS4 and we found that 30 and 100μM of CNS4 selectively potentiates ionic currents for GluN2C and GluN2D subunits with 0.3μM Glu/100μM Gly but inhibited currents for only GluN2D with 300μM Glu/100μM Gly. Following this, a current-voltage plot was made to examine the channel activity of CNS4. We found a numerical increase of ionic inward current through the channel pore with more positive membrane potential values in the GluN2C and GluN2D subunits. Also, the effect of CNS4 on the ion current activity changed based on glutamate concentration, and CNS4 did not exhibit a voltage-dependent activity, which is a positive feature for compounds that target the receptor133. Finally, to better understand the effect of the compound CNS4 in primary neurons in a toxic environment, a rat brain neuronal culture was made. Increasing doses of NMDA with constant 100µM CNS4 increased cellular Ca2+ influx in a dose-dependent manner. Particularly, 100µM CNS4 with 300µM NMDA exhibited a significant increase in Ca2+ influx in both cortical and striatal neurons compared with 300µM NMDA alone. However, when used alone, 100µM CNS4 did not have an effect on the amount of Ca2+ influx. In addition, CNS4 plus NMDA did not increase viability compared to NMDA alone, and CNS4 alone did not proportionally reduce neuronal viability.

L’effet neuroprotecteur des agents anesthésiques est maintenant établi depuis plus de 30ans. Cependant, les mécanismes impliqués restent imparfaitement élucidés. A cours de cetravail nous avons étudié deux volets de leur protection :La première partie porte sur l’implication de la transmission glutaminergique dans leurseffets neuroprotecteurs directs, c'est-à-dire lorsqu’ils sont utilisés au cours d’une l’ischémiecérébrale. Nous avons étudié deux agents anesthésiques de classe distincte: le propofol et lesévoflurane sur des co-cultures de neurones et d’astrocytes corticaux de rat soumis à uneprivation en oxygène et en glucose transitoire (POG). Nous avons ainsi observé que laprésence de propofol ou de sévoflurane pendant la POG prévenait la mort neuronale,l’accumulation de glutamate extracellulaire et la diminution de la capture du glutamateinduites par l’ischémie. Nous avons également montré que cette restauration partielle del’activité de capture du glutamate impliquait des transporteurs distincts entre le propofol et lesévoflurane.La deuxième partie a porté sur la neuroprotection obtenue par un préconditionnement (PC)pharmacologique liée à l’utilisation avant l’ischémie d’agents anesthésique volatils. Nousavons tout d’abord confirmé in vitro l’existence d’une telle protection avec le sévoflurane etmis en évidence le rôle primordial, au cours de cette protection, des canaux potassiques ATPdépendantset des radicaux libres. Puis sur un modèle in vivo d’occlusion transitoire del’artère cérébrale moyenne, le PC par sévoflurane a induit une neuroprotection supérieure àcelle obtenue avec l’utilisation de sévoflurane uniquement pendant l’ischémie. Cependantcette protection est transitoire et ne perdure pas dans le temps. Le sévoflurane ne fait queretarder, sans l’empêcher, la mort neuronale liée à l’apoptose. Il offre cependant une fenêtrethérapeutique intéressante. / The neuroprotective effect of anesthetic agents is now established for over 30 years.However, the mechanisms involved remains to be fully explored. This work focuses on twoneuroprotective strategies:The first part is on the involvement of glutamatergic transmission in their directneuroprotective effects. We studied the effect of two separate classes of anesthetic agents:propofol and sevoflurane on co-cultures of cortical neurons and astrocytes from rats subjectedto a transient oxygen and glucose deprivation (OGD) mimicking cerebral ischemia. Weobserved that the presence of propofol or sevoflurane during OGD prevented neuronal death,accumulation of extracellular glutamate and decreased uptake of glutamate induced byischemia. We also demonstrated that this partial restoration of glutamate uptake mediated bypropofol and sevoflurane involved differential transporters.The second part deals with the neuroprotection achieved by pharmacologicalpreconditioning with regard to the use of volatile anesthetic agents before ischemia. We firstconfirmed in vitro the existence of such protection with sevoflurane. We also highlighted therole of ATP-dependent potassium channels and reactive oxygen species in sevofluranepreconditioning-induced neuroprotection. Then, using an in vivo model of focal transientischemia, we showed that sevoflurane preconditioning significantly improved functionaloutcome and reduced infarct volume. However, this protection was transient. Sevofluraneonly delayed the neuronal death associated with apoptosis but offers an interesting therapeuticwindow.

Introduction: L'injection ip de lipopolysaccharide (LPS) d'E.coli à la rate gestante aboutit à un phénotype cognitivo-comportemental de pathologies neuropsychiatriques chez la progéniture mâle. L'objectif principal était de vérifier l'hypothèse d'une atteinte structurelle et d'un déséquilibre entre excitation et inhibition dans l'hippocampe. L'objectif secondaire était de dégager des stratégies thérapeutiques ciblées.Méthodes: 500 μg/kg de LPS d'E.coli de sérotype O55:B5 ou 2 ml/kg de sérum physiologique étaient injectés ip à la rate au 19e jour de gestation. La progéniture mâle était étudiée à différents stades du développement. L'étude structurelle reposait sur de l'immunohistochimie, l'étude fonctionnelle sur des enregistrements électro-physiologiques de l'activité des cellules pyramidales de l'aire CA1. L'effet protecteur de la N-acétylcystéine (NAC) donnée po à la rate gestante après l'injection de LPS était testé. Résultats: Les animaux soumis à un stress prénatal par le LPS présentaient une désorganisation durable de la couche pyramidale de l'aire CA3, un déficit transitoire de neurones exprimant la reeline, une altération de la dépression à long terme des synapses glutamatergiques (LTDe) liée à un déficit des récepteurs NMDA et du système GABAergique. Un inhibiteur de la recapture du GABA parvenait à corriger les anomalies de la LTDe. La NAC prévenait les anomalies cyto-architecturales.Conclusion: Cette thèse confirme l'impact d'un stress immuno-inflammatoire maternel sur la structure et la fonction hippocampique. Elle démontre l'intérêt d'un traitement prénatal par la NAC et de la modulation du tonus GABAergique pour corriger les troubles cognitifs associés. / Introduction: A late gestational exposure to lipopolysaccharide (LPS) leads to a behavioral and cognitive phenotype of neuropsychiatric disorders in male offspring. The main goal was to test the hypothesis of structural damage and imbalance between excitation and inhibition in the hippocampus. The secondary goal was to identify targeted therapeutic strategies.Methods: Pregnant rats were ip injected with either 500 μg/kg LPS from E.coli O55:B5 or 2 ml/kg saline vehicle on gestational day 19. Male offspring were studied at different developmental stages. The structural study was based on immunohistochemistry, the functional study on electrophysiological recordings of the activity of pyramidal cells in the CA1 area. The protective effect of N-acetylcysteine (NAC) given to pregnant rats after LPS injection was tested.Results: In male offspring, LPS induced late gestational immune challenge led to sustainable disarray of the pyramidal layer in the CA3 area, transient deficit of reelin expressing neurons, impaired long term depression of glutamatergic synapses (LTDe), due to NMDA receptor and GABAergic system dysfunction. An inhibitor of GABA reuptake completely restored plasticity lost after prenatal stress. NAC prevented cyto-architectural abnormalities.Conclusion: This thesis confirms the impact of a late prenatal immune challenge on hippocampal structure and function. It demonstrates that prenatal treatment with NAC and GABAergic tone modulation are valuable therapeutic strategies for the cognitive impairment associated with prenatal immune challenge.

Les récepteurs NMDA (rNMDAs) sont des récepteurs-canaux membranaires activés par le glutamate, neurotransmetteur excitateur, et impliqués dans diverses formes de plasticité synaptique et pathologies. Ces hétérotétramères obligatoires opèrent en dimère-de-dimères, associant généralement deux sous-unités GluN1 et deux GluN2A-D. Déterminer l'arrangement spatial des sous-unités d'un rNMDA est essentiel à la compréhension des mécanismes régissant son fonctionnement et du rôle joué par les interfaces entre sous-unités et entre domaines, notamment N-terminal (NTD) et de liaison des agonistes (ABD). En combinant modélisation moléculaire, mutagenèse dirigée, biochimie sur cystéines et électrophysiologie, nous montrons que ces sous-unités s'arrangent selon un ordre alterné, avec les sous-unités identiques diamétralement opposées, et révélons l'existence d'une interface inter-dimère entre les ABDs GluN1. Nous avons aussi implémenté dans les ovocytes de Xénope une technique innovante consistant à incorporer un acide-aminé non-naturel photo-réactif (UAA) dans un rNMDA. Cette approche, basée sur l'expansion du code génétique, a permis de créer un rNMDA sensible à la lumière. L'introduction d'UAAs aux interfaces entre sous-unités GluN1 et GluN2, révèle le rôle joué par deux de ces interfaces: (1) entre les lobes supérieurs des NTDs, dans le contrôle "sous-unité spécifique" de l'activité et (2) entre les lobes inférieurs des ABDs, dans l'inhibition allostérique par le zinc. Ces travaux apportent des informations sur l'architecture moléculaire des rNMDAs et révèlent l'importance des réarrangements structuraux aux interfaces entre sous-unités voisines dans les fonctions du récepteur. / NMDA receptors (NMDARs) are excitatory neurotransmitter receptors that form glutamate-gated ion channels and are essential mediator of synaptic plasticity and brain disorders. NMDARs are obligatory heterotetramers usually composed of two GluN1 and two GluN2 (A-D) subunits. Whereas it's well established that NMDARs operate as dimers of dimers, subunit arrangement around the central pore is still debated. This issue is fundamental to understand the mechanisms which govern NMDAR functions and the role of the interfaces between subunits and between domains, including the N-terminal domain (NTD) and the agonist-binding domain (ABD). By combining computational modeling, site-directed mutagenesis, electrophysiology, and cysteine cross-linking, we show that, in a full-length heterotetrameric NMDAR, the subunit arrangement is alternated, with identical subunits facing each other, and identify a new interdimer interface between the two GluN1 ABDs. We have also used a new technique, for which we demonstrated the feasibility in Xenopus oocytes, which consists in incorporating photoreactive unnatural amino-acids (UAAs) at different positions in NMDAR subunits. This genetic code expansion enabled us to create photosensitive NMDARs and probe new interfaces between GluN1 and GluN2 and their role in (1) subunit-specific channel activity (interface between GluN1 and GluN2A-B NTDs upper lobes) and (2) zinc allosteric inhibition (interface between GluN1 and GluN2A ABDs lower lobes). Our studies provide new information about molecular architecture of NMDARs and demonstrate the importance of some structural rearrangements between subunit interfaces for the receptor functions.

L-glutamate plays a vital role in central nervous system. It is a neurotransmitterassociated with several neurological disorders like Parkinson's disease, epilepsyand stroke. Continuous and fast monitoring of this neurotransmitter has become amajor concern for neuroscientists throughout the world. A simple, sensitive, and reliable L-glutamate microsensor with short responsetime has been developed using ceramic-based microelectrode arrays with platinum recording sites. The electrodes were modified by electrodeposition of Platinum black (Pt-black) to detect hydrogen peroxide (H2O2) which was produced by enzymatic reactions of glutamate oxidase immobilized on the electrode surface. Modification of Pt electrodes with Pt-black has been adoptedbecause the microscale roughness of Pt-black increases the effective surface area of the electrode and promotes efficiency of H2O2 electro-oxidation. The modified Pt recording sites were coated with m-phenylenediamine (mPD) and L-glutamate oxidase (L-GluOx). mPD acts as an barrier for extracellular interferents such as ascorbic acid and dopamine, thus increasing the selectivity of electrode for Glutamate (Glu). This modified microsensor was highly sensitive to H2O2(686.3??156.48 ??AmM-1cm-2), and Glutamate (492.2??112.67 ??AmM-1cm-2) at 700mV versus Ag/AgCl reference. Deposition of Pt nano-particles on recording sites enhanced the sensitivity to H2O2 by 2 times and the sensitivity to glutamate by 1.5 times.

Aromatase is an enzyme that converts androgens to estrogens. In teleosts, brain aromatase, also known as aromatase B (cy19a1b), is only expressed in radial glial cells (RGCs). This is in contrast to aromatase A, which is expressed in gonads. Estrogens such as estradiol (E2) modulate neurogenesis in the adult teleost brain. Recent studies show that E2 also differentially regulates aromatase B expression in goldfish RGCs. As a result, teleost RGCs are suggested to be involved in regulating neurogenesis. In addition, aromatase B expression in goldfish RGC is under the control of dopamine suggesting that neurons and neurotransmitters can regulate RGC function. Interestingly, goldfish RGC transcriptome data shows the expression of one group of metabotropic glutamate receptors (mGluRs), group III mGluRs, which suggests that glutamate may affect RGC function. In this thesis, I present my findings regarding potential glutamatergic regulation of RGCs. Firstly, I investigated the distribution of glutamatergic synaptic vesicles and RGCs in the female goldfish forebrain. Double-staining immunohistochemistry shows that vesicular glutamate transporter (vGLUT) 1/2-labelled glutamatergic synaptic vesicles are in close anatomical proximity to aromatase B-labelled RGCs, which suggests potential regulation of RGCs by glutamate. Glutamatergic regulation of cyp19a1b, cyclin D1 (ccnd1), cyclin A2 (ccna2), mGluR6b (grm6b), mGluR7 (grm7), and mGluR8b (grm8b) expression in cultured adult female goldfish RGCs was also examined. Results from pharmacological manipulations and qPCR data analysis show that selective activation of group III mGluRs decreased cyp19a1b, ccnd1, and ccna2 mRNA via inhibition of cAMP/PKA signalling. Furthermore, grm7 mRNA is positively regulated by cAMP-dependent signalling. The glutamate analog L-glutamic acid decreased cyp19a1b mRNA and increased ccnd1 and grm6b mRNA in a dose-dependent manner. This suggests that ccnd1 and grm6b expression may be regulated by glutamate receptors other than group III mGluRs, for example, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are expressed in cultured goldfish RGCs. It was found that E2 upregulated cyp19a1b, ccnd1 and grm7 mRNA. However, selective activation of group III mGluRs decreases the stimulatory effect of E2 on ccnd1 expression. My findings show that glutamate finely regulates RGC neurogenic and steroidogenic genes, which may implicate glutamate in the regulation of RGC differentiation, RGC proliferation, and neurogenesis in surrounding cells.

La L-Théanine (L-5-N-éthylglutamine) est un acide aminé présent dans le thé vert et qui a une structure similaire à celle de l'acide glutamique, le neurotransmetteur majoritaire du système nerveux central, SNC. La L-théanine possède la capacité de traverser la barrière hémato-encéphalique en plus de ses nombreuses activités physiologiques et pharmacologiques, anxiolytique et relaxante. La théanine et ses dérivés sont donc considérés comme des outils indispensables pour la compréhension de la synapse glutamatergique plus précisément. Nous avons synthétisé la théanine énantiomériquement pure (L et D). Nous avons développé deux nouvelles méthodes de synthèse de la théanine optiquement pure. Ensuite, nous avons décrit la préparation des dérivés 5-N-alkylés de la théanine et les dipeptides -glutamique en tant qu'analogues 5-N-substitués de la théanine. Dans le but d'élargir l'éventail d'applications de la Théanine ayant un intérêt biologique, nous avons synthétisé des dipeptides contenant la Théanine. Nous présentons également un accès aux dérivés 4-arylés de la théanine, via une alkylation régio et stéréosélective de l'acide pyroglutamique jamais décrit dans la littérature. L'analyse rigoureuse des intermédiaires réactionnels et des produits finaux par les RX, la RMN 1H à 600 MHZ et l'HRMS a prouvé l'obtention d'un seul diastéréoisomère (2S, 4R)-4-aryle théanineLes résultats des tests biologiques, utilisant la technique de l'imagerie calcique, montrent que les deux énantiomères L et D de la théanine possède un effet agoniste vis-à-vis les récepteurs NMDA et que cet effet est beaucoup plus important dans le cas de l'énantiomère (D). Parmi les analogues 5-N-alkylés de la théanine ayant un effet agoniste spécifique des récepteurs NMDA, la 5-N-Propyl-Gln (L et D) montre une activité en tant qu'agoniste beaucoup plus importante que la théanine même (naturelle ou synthétique) et aucun effet n'a été observé sur les récepteurs AMPA et métabotropiques. La L-théanine et ses dérivés pourraient donc être des structures intéressantes pour développer de nouveaux outils pharmacologiques nécessaires à l'étude des récepteurs glutamatergiques (métabotropiques et/ ou ionotropiques). / L-Theanine (5-N-L-ethylglutamine) which is an amino acid found in green tea, it has a structure similar to that of glutamic acid. L-theanine has the ability to cross the blood-brain barrier in addition to its physiological and pharmacological activities.Given the importance of this molecule as essential for the investigation of physiological roles of CNS tools, we synthesized the enantiomerically pure theanine (L and D). A serie of 5-N-substituted theanine were also synthesized. In order to broaden the range of applications of theanine, we synthesized dipeptides containing Theanine for the purpose of obtaining products that have biological significance. The regio and stereoselectively synthesized analogs of L-theanine in the 4-position substituted with an aryl group has been developed to be tested at the level of glutamate receptors.The results of biological tests, using calcium imaging technique, show that theanine with its two enantiomers (D and L) has an agonistic effect vis-à-vis the NMDA receptors and that this effect was much greater with the enantiomer (D). Among the 5-N-alkylated analogs of theanine which they had only an agonistic effect on the NMDA receptor, 5-N-Propyl-Gln (L and D) has activity as an agonist much larger than the theanine and no effects were scored on AMPA receptors and metabotropic. L-theanine and its derivatives could be interesting structures to develop new pharmacological tools to study glutamate receptors (metabotropic and / or ionotropic).

Les récepteurs 5-HT2A de la sérotonine et mGlu2 du glutamate suscitent un grand intérêt vu la dérégulation des deux récepteurs observée dans la schizophrénie et leur statut de cibles des antipsychotiques dits atypiques et de nouvelle génération, respectivement. Même si les antipsychotiques atypiques ciblant le récepteur 5-HT2A ont montré une efficacité contre les symptômes positifs, leur effet reste très limité contre les symptômes négatifs et cognitifs, et leurs effets secondaires nombreux. Depuis les années 1990, une nouvelle classe d’antipsychotiques ciblant le système glutamatergique, en particulier le récepteur mGlu2, est en développement. Les tests cliniques n’ont montré leur efficacité que pour les patients n’ayant pas été traités auparavant par des antipsychotiques atypiques. Ceci suggère une interaction fonctionnelle forte entre les récepteurs 5-HT2A et mGlu2 dans le mode d’action de ces deux classes d’antipsychotiques. De plus, plusieurs études ont démontré l’existence d’un hétéromère des deux récepteurs dans le cortex préfrontal qui semble important pour la réponse aux hallucinogènes et aux antipsychotiques ciblant l’un ou l’autre récepteur. Ainsi, étant donné l’impact du profil de phosphorylation adopté par les récepteurs couplés aux protéines G (RCPG) sur leur fonction, j’ai caractérisé au cours de ma thèse l’impact de la co-expression du récepteur 5-HT2A sur le profil de phosphorylation du récepteur mGlu2 en réponse à différentes stimulations. Parmi les 5 sites de phosphorylation identifiés, la phosphorylation de la Ser843 est potentialisée en réponse à la stimulation par un agoniste du récepteur mGlu2 uniquement lorsque le récepteur 5-HT2A est co-exprimé. Ces résultats ont été validés grâce à la génération d’un nouvel anticorps dirigé spécifiquement contre la forme phosphorylée de la Ser843 sur culture cellulaire HEK-293 et in vivo dans le cortex préfrontal de souris, région où les deux récepteurs sont co-exprimés. Des études fonctionnelles ont démontré que la phosphorylation de la Ser843 est nécessaire à la potentialisation de l’activité Gi/o du récepteur mGlu2 en réponse à ses agonistes et constitue un cross-talk fonctionnel entre les deux récepteurs puisque les agonistes du récepteur 5-HT2A stimulent également la phosphorylation de la Ser843 du récepteur mGlu2. Ainsi, mes résultats de thèse ont permis d’identifier la phosphorylation du récepteur mGlu2 sur la Ser843 comme un événement moléculaire clé du cross-talk fonctionnel avec le récepteur 5-HT2A et apporte un élément important dans la compréhension du mode d’action des antipsychotiques atypiques et de nouvelle génération. / The serotonin 5-HT2A and glutamate mGlu2 receptors keep on attracting particular attention given their implication in psychosis associated with schizophrenia and in the mechanism of action of atypical antipsychotics and of a new class of antipsychotics, respectively. Though atypical antipsychotics, targeting 5-HT2A receptor, are efficient against positive symptoms, these drugs do not act against negative, cognitive symptoms and display many side effects. Since the 90’s, new classes of antipsychotics triggering glutamatergic system, in particular mGlu2 receptor, have been developed. Their clinical trials have shown efficacy only in patients who have not been previously treated with atypical antipsychotics. This suggests a strong interaction between 5-HT2A and mGlu2 receptors in the mechanism of action of both classes of antipsychotics. Moreover, a large body of evidence indicates the presence, in prefontal cortex, of 5-HT2A/mGlu2 heteromer that is important for the response to hallucinogens and antipsychotics targeting one receptor or the other. Thus, in view of the importance of the phosphorylation profile adopted by G-protein coupled receptor (GPCR) on their activity, I characterized the impact of 5-HT2A receptor co-expression on the phosphorylation profile of mGlu2 receptor in response to various stimulations. Among the five identified phosphorylated residues, the phosphorylation of Ser843 increases upon mGlu2 receptor stimulation only when the 5-HT2A receptor is co-expressed. A new antibody against the phosphorylated form of Ser843 confirmed these results in HEK-293 cells and in mouse prefrontal cortex, area where both receptors are co-expressed. Functional studies demonstrated that Ser843 phosphorylation is necessary to enhance Gi/o signaling of mGlu2 receptor and constitutes a functional crosstalk between 5-HT2A and mGlu2 receptor since 5-HT2A receptor agonists also stimulate Ser843 phosphorylation. Collectively, my thesis findings identify mGlu2 receptor phosphorylation at Ser843 as a key molecular event of the functional crosstalk with 5-HT2A receptor that might be critical to understand the mechanism of action of atypical and potential future antipsychotics treatments.

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / A Riparina IV, uma alcamida sintetizada de Aniba riparia, foi testada em modelos animais padronizados de dor, bem como os possÃveis mecanismos de aÃÃo envolvidos. Foram utilizados camundongos Swiss (20-30g), e a Riparina IV foi administrada de forma aguda em todos os testes, nas doses de 25 e 50 mg/kg, por via oral. Foram utilizados os testes de contorÃÃes abdominais induzidas por Ãcido acÃtico; placa quente; teste da formalina; hipernocicepÃÃo mecÃnica induzida pela carragenina; teste da nocicepÃÃo induzida por capsaicina, cinamaldeÃdo, mentol; teste da nocicepÃÃo induzida por glutamato, bem como em modelos comportamentais que permitam excluir a possibilidade de uma atividade relaxante muscular ou induzir resultados falso-positivos nos modelos anteriores, tais como testes do campo aberto e rota Rod. Os resultados demonstraram que a Riparina IV possui uma atividade antinociceptiva no modelo de nocicepÃÃo visceral induzida por Ãcido acÃtico. A Riparina IV nÃo demonstrou atividade no modelo de nocicepÃÃo tÃrmica da placa quente. O prÃ-tratamento com a Riparina IV reduziu significativamente a nocicepÃÃo inflamatÃria induzida pela segunda fase da formalina, porÃm nÃo alterou a nocicepÃÃo neurogÃnica induzida pela primeira fase do teste da formalina. Os animais prÃ-tratados com a Riparina IV tambÃm exibiram uma reduÃÃo significativa na hipernocicepÃÃo mecÃnica induzida pela carragenina. Em relaÃÃo à participaÃÃo dos receptores de potencial transitÃrio (TRP), a Riparina IV demonstrou atividade nos modelos de nocicepÃÃo induzida pela administraÃÃo de capsaicina e mentol, porÃm nÃo apresentou atividade na nocicepÃÃo induzida por cinamaldeÃdo. TambÃm reduziu a nocicepÃÃo induzida pela administraÃÃo intraplantar de glutamato. Para o estudo dos mecanismos de aÃÃo da Riparina IV foi utilizada somente a dose de 50 mg/kg da substÃncia. Na avaliaÃÃo da participaÃÃo dos canais de potÃssio ATP-dependentes, o prÃ-tratamento com glibenclamida nÃo foi capaz de reverter a aÃÃo antinociceptiva da Riparina IV, descartando-se o seu envolvimento; da mesma forma, o prÃ-tratamento com ioimbina, um antagonista α2-adrenÃrgico, e pCPA, um depletor das reservas de serotonina, tambÃm nÃo foram capazes de reverter tal aÃÃo, nÃo havendo envolvimento com o mecanismo de aÃÃo da Riparina IV. O prÃ-tratamento com L-arginina, um precursor do Ãxido nÃtrico, reverteu a aÃÃo antinociceptiva da Riparina IV, sugerindo, em parte, a participaÃÃo da via do Ãxido nÃtrico no seu mecanismo de aÃÃo. Os resultados mostraram que essa substÃncia nÃo alterou a atividade locomotora no teste do campo aberto, nem diminuiu o nÃmero de quedas no teste do rota Rod, descartando a possibilidade de haver sedaÃÃo ou incoordenaÃÃo motora por parte da Riparina IV. Em sÃntese, os resultados demonstraram que a Riparina IV possui uma atividade em modelos animais de nocicepÃÃo, possivelmente envolvendo os receptores TRPV1, TRPM8, glutamatÃrgicos e a via do Ãxido nÃtrico. / Riparin IV, an alkamide synthesized from Aniba riparia, was tested in standard animal models of pain, as well as the possible mechanisms of action involved. It was used Swiss mice (20-30g), and Riparin IV was administred acutely in all tests, at the doses of 25 and 50 mg/kg, by gavage. It was used the tests of abdominal writhing induced by acetic acid, hot plate test, formalin test, mechanical hypernociception induced by carrageenan, nociception test induced by capsaicin, cinnamaldehyde and menthol, nociception test induced by glutamate, as well as models of behavior that ruled out the possibility of a muscle relaxing activity or induce false-positive results in previous models, such as the open field test and the rota Rod test. The results showed that Riparin IV has an antinociceptive activity at the model of visceral nociception induced by acetic acid. Riparin IV did not show any activity at the hot plate thermal nociception model. Pretreatment with Riparin IV reduced significantly the inflammatory nociception induced at the second phase of formalin test, but did not alter the neurogenic nociception induced at the first phase of formalin test. The animals pretreated with Riparin IV also exhibited a significant reduction at the mechanical hypernociception induced by carrageenan. Related to the participation of the Transient Potential Receptors (TRP), Riparin IV showed an activity at the models of nociception induced by capsaicin and menthol, but did not show any activity at the nociception induced by cinnamaldehyde. Also reduced the nociception induced by administration of glutamate at the rind paw. To study the mechanisms of action of Riparin IV, it was used only the dose of 50 mg/kg of the substance. At the evaluation of participation of the ATP-dependent potassium channels, pretreatment with glibenclamide was not able to reverse the antinociceptive action of Riparin IV, discharging its involvment; at the same way, pretreatment with yohimbine, an a2-adrenergic antagonist, and pCPA, a depletor of the serotonin reservations, were not able of reverse such action, not having any involvement with the mechanism of action of Riparin IV. Pretreatment with L-arginine, a precursor of Nitric Oxide, reversed the antinociceptive action of Riparin IV, suggesting, in part, the participation of nitric oxide pathway at the mechanism of action. The results showed that this substance did not alter the locomotor activity at the open field test, neither diminished the number of falls at the rota Rod test, discharging the possibility of sedation or incoordination by Riparin IV. In summary, the results showed that Riparin IV has an action in animal models of nociception, possibly involving the receptors TRPV1, TRPM8, glutamatergic receptors and the nitric oxide pathway.